Cathay Biotech Inc. (SHA:688065)

Market Cap	30.38B -20.7%
Revenue (ttm)	3.39B +11.3%
Net Income	589.49M +13.2%
EPS	0.82 -7.4%
Shares Out	720.66M
PE Ratio	51.14
Forward PE	34.77
Dividend	0.45 (1.04%)
Ex-Dividend Date	Aug 1, 2025

Volume	6,933,488
Average Volume	6,060,797
Open	43.18
Previous Close	43.46
Day's Range	41.85 - 43.39
52-Week Range	41.90 - 64.50
Beta	0.60
RSI	28.09
Earnings Date	Aug 14, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, perfumes, aut...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,761
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2025, Cathay Biotech's revenue was 3.30 billion, an increase of 11.40% compared to the previous year's 2.96 billion. Earnings were 560.72 million, an increase of 14.68%.